image descriptionimage description

If you’re experiencing the back pain and stiffness of ankylosing spondylitis, talk to your rheumatologist about HUMIRA

If your symptoms are continuing to impact you, there are other treatment options that have been proven effective in treating ankylosing spondylitis.

The government medicine funding agency, PHARMAC, fully subsidises HUMIRA if your ankylosing spondylitis has not fully responded to other medicines prescribed by a specialist, and you meet other criteria required by PHARMAC. Your specialist will discuss whether HUMIRA is right for you, and whether you may qualify for PHARMAC funded treatment.

Is it time to consider another ankylosing spondylitis treatment? Ask about HUMIRA

The back pain and stiffness of ankylosing spondylitis can be severe and some people find that conventional medicines and treatments, such as nonsteroidal anti-inflammatory drugs (NSAIDs), may not do enough to relieve their symptoms.

HUMIRA is a biologic medicine that works by identifying and blocking a specific source of inflammation that contributes to ankylosing spondylitis symptoms, and it may be an option for you.

HUMIRA treatment is only available on prescription, so if you are still experiencing the symptoms of ankylosing spondylitis despite your current treatment, talk to your rheumatologist to see if HUMIRA is right for you.

HUMIRA helps reduce pain and stiffness in many adults

Based on clinical studies in adults with active ankylosing spondylitis, it is expected that nearly 60% of people may expect to have a reduction in symptoms with HUMIRA after 12 weeks of treatment.1 People can expect a reduction in signs and symptoms for up to 24 weeks and longer.1-3

ASAS stands for ‘Assessment of SpondyloArthritis’ (ankylosing spondylitis) which is a measure of disease activity. ASAS 20 includes an improvement of at least 20% in at least three important areas (pain, inflammation, function and patient global assessment) which has been used in clinical trials to assess what is a meaningful reduction in symptoms.

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. van der Heijde D et al. Arth & Rheum. 2006;54(7):2136-46
  2. Maksymowych WP et al. J Rheumatol. 2010; 37:385–92
  3. Sieper J, van der Heijde D, Dougados M, et al. Ann Rheum Dis. 2012;71(5):700-6
NZ-HUM-0118 TAPS PP9594  Prepared May 2017

Learn how HUMIRA works

Watch this short video to get a better understanding of how HUMIRA targets and helps to block TNF.

How HUMIRA treatment works video transcript

Usually, your immune system defends your body from many of the things that can harm it. But when the system doesn’t work right, it can attack healthy tissues and organs. This is an autoimmune disease. One part of your immune system is a protein called TNF, which is produced naturally by the body’s immune system. But in certain autoimmune diseases, some people produce too much TNF. This often leads to inflammation. HUMIRA is a medication called a TNF blocker. It works by binding to TNF molecules and blocking them from attaching to and making cells behave in a way which leads to effects on health. In this way, HUMIRA helps reduce the damaging effects of excess TNF. Remember, although HUMIRA can’t stop your body’s overproduction of TNF it can reduce its effects.

The immune system can overproduce the TNF protein, which is one source of inflammation that contributes to the symptoms of ankylosing spondylitis. HUMIRA targets and helps block TNF (a particular protein), reducing its inflammatory effects on the joints, causing the back pain and stiffness of ankylosing spondylitis.

Talk to your rheumatologist about whether HUMIRA is right for treating your ankylosing spondylitis

References:
All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. van der Heijde D et al. Arth & Rheum. 2006;54(7):2136-46
  2. Maksymowych WP et al. J Rheumatol. 2010; 37:385–92

NZ-HUM-0118 TAPS PP9594 Prepared May 2017

Find out what you may expect when you start treatment with HUMIRA for ankylosing spondylitis

You can expect to see improvement in signs and symptoms of ankylosing spondylitis in as little as 2 weeks in some people, however it may take up to 3 months or longer to notice improvement.1

Start out on the right path by learning how to take HUMIRA correctly

The usual recommended dose for adults with ankylosing spondylitis is a 40mg injection once every two weeks. Your rheumatologist will decide what dosage of HUMIRA you require and how often you need to administer the injection. Only inject as prescribed by them.

Humira is given by injection just under the skin. HUMIRA is available in either a pre-filled single use syringe, or pre-filled single-use auto-injector pen and both come pre-loaded with the exact dose of medicine inside, so it comes ready to inject and you can do it by yourself. Your rheumatologist or nurse will be able to help you and be with you for your first injection however before long you will be able to do it by yourself, or if not, it can be given by another healthcare professional or a family member or friend after they have been trained to give injections. Also, for people on HUMIRA in New Zealand you can join the AbbVie Care support programme with access to a nurse to help you.

Watch these short videos to get a better understanding of how to inject HUMIRA.

Pen video also available in the following languages:
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0046

Syringe video also available in the following languages:    
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0047

Storage and travelling with HUMIRA

Keep HUMIRA in the outer carton until it is time to use it. HUMIRA must be kept in the refrigerator (+2° C to +8° C) but don’t allow it to freeze. If you are travelling the HUMIRA pre-filled pen or pre-filled syringe may be stored at room temperature (below +25° C) for a maximum period of 14 days, but it must be protected from light. Once removed from the refrigerator for room temperature storage, the syringe or pen must be used within 14 days or discarded even if it is returned to the refrigerator. If additional syringes or pens are being carried, they should be refrigerated (kept between 2°C–8°C).

Join AbbVie Care to receive an ice pack and order a travel wallet through www.abbviecare.co.nz or call 0800 848 243.

When planning to travel overseas it is important that you:

  • talk to your doctor about travelling with HUMIRA
  • carry a letter from your doctor detailing what HUMIRA is, how much you will be taking, and stating that it is for your own personal use
  • leave HUMIRA in its original packaging so it is clearly labeled with your name and dosage instructions (if you are taking HUMIRA pens/syringes with you)


AbbVie Care Support Programme helps take care of you

AbbVie Care is available to you when you are taking HUMIRA. Support from AbbVie Care is designed to complement the care you receive from your specialist and clinic nurse.
AbbVie Care provides personalised support to meet each person’s needs. The aim is by working together people can achieve better outcomes with their health and quality of life.

It’s easy to ENROL

JOIN AbbVie Care to get the best out of your HUMIRA treatment
• Go online to www.abbviecare.co.nz
• Call 0800 848 243

How AbbVie Care supports you:

AbbVie Care Nurse

AbbVie Care Nurse Support

– Home visits or phone calls to help with injecting^
– Scheduled phone calls to provide information and support
– An 0800 number to call when you have a question

www.abbviecare.co.nz

www.AbbVieCare.co.nz

– Helpful resources and tools (ie. travel advice)
– The ability to order your sharps container and travel wallet online
– Medication and appointment reminders
– Visit www.abbviecare.co.nz

AbbvieCare_online-com

Online Community

– Connecting you to others on HUMIRA
– Contact with your AbbVie Care Nurse

AbbvieCare Sharps Disposal Programme

Sharps Disposal Programme

– Delivery of sharps container to safely dispose of your HUMIRA pens and syringes
– Access to pharmacy disposal of your sharps container

AbbvieCare Travel Wallet

Travel Wallet

– Designed to make travelling with HUMIRA safer and easier

Abbvie_Care_Welcome_Kit

Welcome Kit

– Information on all you need to know to get the best out of AbbVie Care
– Ice pack to assist with injecting


References:
All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.
^Home visits do not cover all of New Zealand. Your AbbVie Care Nurse will be able to discuss this with you when you join AbbVie Care.

  1. van der Heijde D et al. Arth & Rheum. 2006;54(7):2136-46
  2. Maksymowych WP et al. J Rheumatol. 2010; 37:385–92

NZ-HUM-0118 TAPS PP9594 Prepared May 2017

The following resources have been compiled to help you get support outside the HUMIRA AbbVie Care programme. We hope you find them useful.

Arthritis New Zealandlogo_Arthritis-New-Zealand

A national voluntary organisation which represents the interests of those with arthritis. Information on the condition and its treatment.
www.arthritis.org.nz

Arthritis Australia

www.arthritisaustralia.com.au

Spondylitis Association of America

www.spondylitis.org

Arthritis Foundation USA

www.arthritis.org

New Zealand Rheumatology Association

www.rheumatology.org.nz

American College of Rheumatology

www.rheumatology.org

Australian Rheumatology Association

www.rheumatology.org.au

Don’t Turn Your Back On ItDont-Turn-Your-Back-Logo

An AbbVie organised and sponsored website to help identify inflammatory back pain and provide tools and guidance for your next steps.
www.dontturnyourbackonit.co.nz

 

References:
All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. van der Heijde D et al. Arth & Rheum. 2006;54(7):2136-46
  2. Maksymowych WP et al. J Rheumatol. 2010; 37:385–92

NZ-HUM-0118 TAPS PP9594 Prepared May 2017